PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
申请人:Mitobridge, Inc.
公开号:US10188627B2
公开(公告)日:2019-01-29
Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
申请人:Mitobridge, Inc.
公开号:US20170304255A1
公开(公告)日:2017-10-26
Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
[EN] PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF<br/>[FR] AGONISTES, COMPOSÉS, COMPOSITIONS PHARMACEUTIQUES PPAR ET MÉTHODES D'UTILISATION DE CEUX-CI
申请人:MITOBRIDGE INC
公开号:WO2016057660A1
公开(公告)日:2016-04-14
Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
申请人:Molino F. Bruce
公开号:US20070021408A1
公开(公告)日:2007-01-25
The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II):
where the carbon atom designated * is in the R or S configuration, and the substituents X and R
1
-R
9
are as defined herein.